TY  - GEN
AU  - Saiz,Juan Carlos
AU  - Saiz,Juan Carlos
TI  - Vaccines against RNA Viruses
SN  - books978-3-03943-624-8
PY  - 2020///
CY  - Basel, Switzerland
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - Medicine
KW  - bicssc
KW  - artificial protein
KW  - polyepitope B- and T-cell HIV-1 immunogen
KW  - epitopes of broadly neutralizing HIV-1 antibodies
KW  - peptide mimic of discontinuous epitope
KW  - immunogenicity
KW  - birds
KW  - vaccines
KW  - West Nile virus
KW  - flavivirus
KW  - herd immunity
KW  - porcine epidemic diarrhea virus
KW  - RNA interference
KW  - processivity factor
KW  - intestine epithelial cells
KW  - N gene
KW  - rotavirus nanoparticle vaccine
KW  - gnotobiotic pigs
KW  - FMDV
KW  - peptide vaccine
KW  - single dose
KW  - amount
KW  - pig
KW  - VHSV
KW  - non-virion (NV)
KW  - transcriptome profiling
KW  - rainbow trout
KW  - immune pathways
KW  - Rift Valley fever virus (RVFV)
KW  - modified vaccinia Ankara (MVA)
KW  - cellular response
KW  - neutralizing antibodies
KW  - Gn Gc glycoproteins
KW  - passive serum:virus transfer
KW  - hepatitis C virus
KW  - neutralising antibodies
KW  - animal models
KW  - immune responses
KW  - PRRSV Mosaic T-cell DNA vaccine VACV
KW  - PRRS
KW  - cross protection
KW  - heterologous virus challenge
KW  - n/a
N1  - Open Access
N2  - RNA viruses cause animal, human, and zoonotic diseases that affect millions of individuals, as is being exemplified by the devastating ongoing epidemic of the recently identified SARS-Cov-2. For years vaccines have had an enormous impact on overcoming the global burden of diseases. Nowadays, a vast number of different approaches, from purified inactivated and live attenuated viruses, nucleic acid (DNA or RNA) based candidates, virus-like particles, subunit elements, and recombinant viruses are been employed to combat viruses. However, for many of them efficient vaccines are not yet available. This will probably change dramatically with the current Covid-19 pandemic, as a vast variety of vaccinology approaches are being tested against it, with hundreds of candidates under development, dozens of them already in clinical trials, a fact that is breaking records in vaccine development and implementation. This is becoming possible thanks to the enormous work carried out during years to have the bases for a quick response, even against unknown pathogens, in an impressive short time. Here, results obtained with different vaccine´s methodological approaches against human (HIV, HCV, HRV) animal (PRRSV, PEDV, FMDV, VHSV) and zoonotic (RVF, WNV), RNA viruses are presented by field experts
UR  - https://mdpi.com/books/pdfview/book/3253
UR  - https://directory.doabooks.org/handle/20.500.12854/69449
ER  -